Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 27 entries
Sorted by: Best Match Show Resources per page
Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting.

Cancer management and research

Rapoport BL.
PMID: 28260945
Cancer Manag Res. 2017 Feb 22;9:41-50. doi: 10.2147/CMAR.S97543. eCollection 2017.

Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect of many cytotoxic chemotherapy regimens. CINV typically manifests during two well-defined time periods (acute and delayed phases). The acute phase is the first 24 hours after chemotherapy and is...

Cite
Rapoport BL. Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting. Cancer Manag Res. 2017;9:41-50doi: 10.2147/CMAR.S97543.
Rapoport, B. L. (2017). Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting. Cancer management and research, 941-50. https://doi.org/10.2147/CMAR.S97543
Rapoport, Bernardo Leon. "Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting." Cancer management and research vol. 9 (2017): 41-50. doi: https://doi.org/10.2147/CMAR.S97543
Rapoport BL. Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting. Cancer Manag Res. 2017 Feb 22;9:41-50. doi: 10.2147/CMAR.S97543. eCollection 2017. PMID: 28260945; PMCID: PMC5327850.
Copy Download .nbib Format: NLM
Retraction notice to 'Corrigendum to "3-Benzhydryl-4-piperidones as novel neurokinin-1 receptor antagonists and their efficient synthesis"' [Bioorg. Med. Chem. 20 (2012) 5668-5668].

Bioorganic & medicinal chemistry

[No authors listed]
PMID: 25756091
Bioorg Med Chem. 2014 Dec 01;22(23):6726. doi: 10.1016/j.bmc.2014.10.019.

No abstract available.

Cite
Retraction notice to 'Corrigendum to "3-Benzhydryl-4-piperidones as novel neurokinin-1 receptor antagonists and their efficient synthesis"' [Bioorg. Med. Chem. 20 (2012) 5668-5668]. Bioorg Med Chem. 2014;22(23):6726doi: 10.1016/j.bmc.2014.10.019.
(2014). Retraction notice to 'Corrigendum to "3-Benzhydryl-4-piperidones as novel neurokinin-1 receptor antagonists and their efficient synthesis"' [Bioorg. Med. Chem. 20 (2012) 5668-5668]. Bioorganic & medicinal chemistry, 22(23), 6726. https://doi.org/10.1016/j.bmc.2014.10.019
"Retraction notice to 'Corrigendum to "3-Benzhydryl-4-piperidones as novel neurokinin-1 receptor antagonists and their efficient synthesis"' [Bioorg. Med. Chem. 20 (2012) 5668-5668]." Bioorganic & medicinal chemistry vol. 22,23 (2014): 6726. doi: https://doi.org/10.1016/j.bmc.2014.10.019
Retraction notice to 'Corrigendum to "3-Benzhydryl-4-piperidones as novel neurokinin-1 receptor antagonists and their efficient synthesis"' [Bioorg. Med. Chem. 20 (2012) 5668-5668]. Bioorg Med Chem. 2014 Dec 01;22(23):6726. doi: 10.1016/j.bmc.2014.10.019. PMID: 25756091.
Copy Download .nbib Format: NLM
Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Escobar Álvarez Y, De Castro Carpeño J, Bell D, Drago A, Franceschetti A.
PMID: 33956310
Clin Transl Oncol. 2021 Oct;23(10):2155-2162. doi: 10.1007/s12094-021-02623-8. Epub 2021 May 06.

PURPOSE: Proper monitoring and management of chemotherapy-induced nausea and vomiting (CINV) with antiemetics is crucial for cancer patients. This study aimed to evaluate the use of antiemetics for the treatment of highly emetogenic chemotherapy (HEC) including carboplatin in the...

Cite
Escobar Álvarez Y, De Castro Carpeño J, Bell D, et al. Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain. Clin Transl Oncol. 2021;23(10):2155-2162doi: 10.1007/s12094-021-02623-8.
Escobar Álvarez, Y., De Castro Carpeño, J., Bell, D., Drago, A., & Franceschetti, A. (2021). Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 23(10), 2155-2162. https://doi.org/10.1007/s12094-021-02623-8
Escobar Álvarez, Y, et al. "Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain." Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico vol. 23,10 (2021): 2155-2162. doi: https://doi.org/10.1007/s12094-021-02623-8
Escobar Álvarez Y, De Castro Carpeño J, Bell D, Drago A, Franceschetti A. Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain. Clin Transl Oncol. 2021 Oct;23(10):2155-2162. doi: 10.1007/s12094-021-02623-8. Epub 2021 May 06. PMID: 33956310; PMCID: PMC8390393.
Copy Download .nbib Format: NLM
The Neuromodulatory Effect of Antipruritic Treatment of Chronic Prurigo.

Dermatology and therapy

Zeidler C, Pereira M, Ständer S.
PMID: 31512177
Dermatol Ther (Heidelb). 2019 Dec;9(4):613-622. doi: 10.1007/s13555-019-00321-6. Epub 2019 Sep 11.

Chronic prurigo is an extremely severe pruritic skin disease which presents with multiple, hyperkeratotic and erosive papules, nodules and/or plaques. Patients with this high-burden disease require effective therapies, but effective treatments with regulatory agency approval are currently lacking. Deeper...

Cite
Zeidler C, Pereira M, Ständer S. The Neuromodulatory Effect of Antipruritic Treatment of Chronic Prurigo. Dermatol Ther (Heidelb). 2019;9(4):613-622doi: 10.1007/s13555-019-00321-6.
Zeidler, C., Pereira, M., & Ständer, S. (2019). The Neuromodulatory Effect of Antipruritic Treatment of Chronic Prurigo. Dermatology and therapy, 9(4), 613-622. https://doi.org/10.1007/s13555-019-00321-6
Zeidler, Claudia, et al. "The Neuromodulatory Effect of Antipruritic Treatment of Chronic Prurigo." Dermatology and therapy vol. 9,4 (2019): 613-622. doi: https://doi.org/10.1007/s13555-019-00321-6
Zeidler C, Pereira M, Ständer S. The Neuromodulatory Effect of Antipruritic Treatment of Chronic Prurigo. Dermatol Ther (Heidelb). 2019 Dec;9(4):613-622. doi: 10.1007/s13555-019-00321-6. Epub 2019 Sep 11. PMID: 31512177; PMCID: PMC6828989.
Copy Download .nbib Format: NLM
Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting.

OncoTargets and therapy

Navari RM, Schwartzberg LS.
PMID: 30323622
Onco Targets Ther. 2018 Oct 04;11:6459-6478. doi: 10.2147/OTT.S158570. eCollection 2018.

To examine pharmacologic and clinical characteristics of neurokinin 1 (NK

Cite
Navari RM, Schwartzberg LS. Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting. Onco Targets Ther. 2018;11:6459-6478doi: 10.2147/OTT.S158570.
Navari, R. M., & Schwartzberg, L. S. (2018). Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting. OncoTargets and therapy, 116459-6478. https://doi.org/10.2147/OTT.S158570
Navari, Rudolph M, and Schwartzberg, Lee S. "Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting." OncoTargets and therapy vol. 11 (2018): 6459-6478. doi: https://doi.org/10.2147/OTT.S158570
Navari RM, Schwartzberg LS. Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting. Onco Targets Ther. 2018 Oct 04;11:6459-6478. doi: 10.2147/OTT.S158570. eCollection 2018. PMID: 30323622; PMCID: PMC6178341.
Copy Download .nbib Format: NLM
Effects of Rolapitant Administered Intravenously on the Pharmacokinetics of a Modified Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan) in Healthy Subjects.

Journal of clinical pharmacology

Wang X, Zhang ZY, Arora S, Wang J, Lu S, Powers D, Kansra V.
PMID: 29693712
J Clin Pharmacol. 2018 Aug;58(8):1074-1083. doi: 10.1002/jcph.1114. Epub 2018 Apr 25.

Rolapitant is a selective, long-acting neurokinin-1 receptor antagonist, approved in the United States and Europe for prevention of delayed chemotherapy-induced nausea and vomiting in adults. This open-label study evaluated the effects of a new intravenous formulation of rolapitant on...

Cite
Wang X, Zhang ZY, Arora S, et al. Effects of Rolapitant Administered Intravenously on the Pharmacokinetics of a Modified Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan) in Healthy Subjects. J Clin Pharmacol. 2018;58(8):1074-1083doi: 10.1002/jcph.1114.
Wang, X., Zhang, Z. Y., Arora, S., Wang, J., Lu, S., Powers, D., & Kansra, V. (2018). Effects of Rolapitant Administered Intravenously on the Pharmacokinetics of a Modified Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan) in Healthy Subjects. Journal of clinical pharmacology, 58(8), 1074-1083. https://doi.org/10.1002/jcph.1114
Wang, Xiaodong, et al. "Effects of Rolapitant Administered Intravenously on the Pharmacokinetics of a Modified Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan) in Healthy Subjects." Journal of clinical pharmacology vol. 58,8 (2018): 1074-1083. doi: https://doi.org/10.1002/jcph.1114
Wang X, Zhang ZY, Arora S, Wang J, Lu S, Powers D, Kansra V. Effects of Rolapitant Administered Intravenously on the Pharmacokinetics of a Modified Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan) in Healthy Subjects. J Clin Pharmacol. 2018 Aug;58(8):1074-1083. doi: 10.1002/jcph.1114. Epub 2018 Apr 25. PMID: 29693712.
Copy Download .nbib Format: NLM
Retraction notice to "3-Benzhydryl-4-piperidones as novel neurokinin-1 receptor antagonists and their efficient synthesis" [Bioorg. Med. Chem. 19 (2011) 5175-82].

Bioorganic & medicinal chemistry

[No authors listed]
PMID: 25671237
Bioorg Med Chem. 2015 Jan 01;23(1):272. doi: 10.1016/j.bmc.2014.11.026.

No abstract available.

Cite
Retraction notice to "3-Benzhydryl-4-piperidones as novel neurokinin-1 receptor antagonists and their efficient synthesis" [Bioorg. Med. Chem. 19 (2011) 5175-82]. Bioorg Med Chem. 2015;23(1):272doi: 10.1016/j.bmc.2014.11.026.
(2015). Retraction notice to "3-Benzhydryl-4-piperidones as novel neurokinin-1 receptor antagonists and their efficient synthesis" [Bioorg. Med. Chem. 19 (2011) 5175-82]. Bioorganic & medicinal chemistry, 23(1), 272. https://doi.org/10.1016/j.bmc.2014.11.026
"Retraction notice to "3-Benzhydryl-4-piperidones as novel neurokinin-1 receptor antagonists and their efficient synthesis" [Bioorg. Med. Chem. 19 (2011) 5175-82]." Bioorganic & medicinal chemistry vol. 23,1 (2015): 272. doi: https://doi.org/10.1016/j.bmc.2014.11.026
Retraction notice to "3-Benzhydryl-4-piperidones as novel neurokinin-1 receptor antagonists and their efficient synthesis" [Bioorg. Med. Chem. 19 (2011) 5175-82]. Bioorg Med Chem. 2015 Jan 01;23(1):272. doi: 10.1016/j.bmc.2014.11.026. PMID: 25671237.
Copy Download .nbib Format: NLM
Neurokinin-1 Receptor Antagonist Can Prevent the Delayed Phase in Patients: A Single Center Retrospect Study.

Anti-cancer agents in medicinal chemistry

Xu J, Tang S, Li J, Wang W, Wu M, Zhan X.
PMID: 33397273
Anticancer Agents Med Chem. 2021 Oct 28;21(16):2192-2197. doi: 10.2174/1871520621999210104194038.

BACKGROUND: Neurokinin-1 receptor antagonists are playing a major advance in Chemotherapy-Induced Nausea and Vomiting (CINV) as powerful prophylactic agents. Therefore, it is significant to find the association between risk factors of patients and CINV so as to adjust the...

Cite
Xu J, Tang S, Li J, et al. Neurokinin-1 Receptor Antagonist Can Prevent the Delayed Phase in Patients: A Single Center Retrospect Study. Anticancer Agents Med Chem. 2021;21(16):2192-2197doi: 10.2174/1871520621999210104194038.
Xu, J., Tang, S., Li, J., Wang, W., Wu, M., & Zhan, X. (2021). Neurokinin-1 Receptor Antagonist Can Prevent the Delayed Phase in Patients: A Single Center Retrospect Study. Anti-cancer agents in medicinal chemistry, 21(16), 2192-2197. https://doi.org/10.2174/1871520621999210104194038
Xu, Jing, et al. "Neurokinin-1 Receptor Antagonist Can Prevent the Delayed Phase in Patients: A Single Center Retrospect Study." Anti-cancer agents in medicinal chemistry vol. 21,16 (2021): 2192-2197. doi: https://doi.org/10.2174/1871520621999210104194038
Xu J, Tang S, Li J, Wang W, Wu M, Zhan X. Neurokinin-1 Receptor Antagonist Can Prevent the Delayed Phase in Patients: A Single Center Retrospect Study. Anticancer Agents Med Chem. 2021 Oct 28;21(16):2192-2197. doi: 10.2174/1871520621999210104194038. PMID: 33397273.
Copy Download .nbib Format: NLM
Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Hata A, Okamoto I, Inui N, Okada M, Morise M, Akiyoshi K, Takeda M, Watanabe Y, Sugawara S, Shinagawa N, Kubota K, Saeki T, Tamura T.
PMID: 34793245
J Clin Oncol. 2021 Nov 18;JCO2101315. doi: 10.1200/JCO.21.01315. Epub 2021 Nov 18.

PURPOSE: We evaluated the efficacy and safety of fosnetupitant (FosNTP) versus fosaprepitant (FosAPR) for preventing highly emetogenic chemotherapy-induced nausea and vomiting. This phase III study was the first head-to-head comparison between two different neurokinin-1 receptor antagonists in combination with...

Cite
Hata A, Okamoto I, Inui N, et al. Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE. J Clin Oncol. 2021;JCO2101315doi: 10.1200/JCO.21.01315.
Hata, A., Okamoto, I., Inui, N., Okada, M., Morise, M., Akiyoshi, K., Takeda, M., Watanabe, Y., Sugawara, S., Shinagawa, N., Kubota, K., Saeki, T., & Tamura, T. (2021). Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2101315. https://doi.org/10.1200/JCO.21.01315
Hata, Akito, et al. "Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. (2021): JCO2101315. doi: https://doi.org/10.1200/JCO.21.01315
Hata A, Okamoto I, Inui N, Okada M, Morise M, Akiyoshi K, Takeda M, Watanabe Y, Sugawara S, Shinagawa N, Kubota K, Saeki T, Tamura T. Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE. J Clin Oncol. 2021 Nov 18;JCO2101315. doi: 10.1200/JCO.21.01315. Epub 2021 Nov 18. PMID: 34793245; PMCID: PMC8718175.
Copy Download .nbib Format: NLM
Neurokinin-1 receptor antagonists: A new revolution in antiretroviral treatment?.

Indian journal of sexually transmitted diseases and AIDS

Grewal US.
PMID: 27890962
Indian J Sex Transm Dis AIDS. 2016 Jul-Dec;37(2):208-209. doi: 10.4103/0253-7184.192126.

No abstract available.

Cite
Grewal US. Neurokinin-1 receptor antagonists: A new revolution in antiretroviral treatment?. Indian J Sex Transm Dis AIDS. 2016;37(2):208-209doi: 10.4103/0253-7184.192126.
Grewal, U. S. (2016). Neurokinin-1 receptor antagonists: A new revolution in antiretroviral treatment?. Indian journal of sexually transmitted diseases and AIDS, 37(2), 208-209. https://doi.org/10.4103/0253-7184.192126
Grewal, Udhayvir Singh. "Neurokinin-1 receptor antagonists: A new revolution in antiretroviral treatment?." Indian journal of sexually transmitted diseases and AIDS vol. 37,2 (2016): 208-209. doi: https://doi.org/10.4103/0253-7184.192126
Grewal US. Neurokinin-1 receptor antagonists: A new revolution in antiretroviral treatment?. Indian J Sex Transm Dis AIDS. 2016 Jul-Dec;37(2):208-209. doi: 10.4103/0253-7184.192126. PMID: 27890962; PMCID: PMC5111313.
Copy Download .nbib Format: NLM
Nausea and vomiting.

Current treatment options in gastroenterology

Chepyala P, Olden KW.
PMID: 18321441
Curr Treat Options Gastroenterol. 2008 Apr;11(2):135-44. doi: 10.1007/s11938-008-0026-6.

Nausea and vomiting are symptoms resulting from a triggered emetic reflex. Many endogenous and exogenous triggering factors can activate the emetic reflex, making understanding difficult and therapy challenging. The key to managing most cases of nausea and vomiting lies...

Cite
Chepyala P, Olden KW. Nausea and vomiting. Curr Treat Options Gastroenterol. 2008;11(2):135-44doi: 10.1007/s11938-008-0026-6.
Chepyala, P., & Olden, K. W. (2008). Nausea and vomiting. Current treatment options in gastroenterology, 11(2), 135-44. https://doi.org/10.1007/s11938-008-0026-6
Chepyala, Pavan, and Olden, Kevin W. "Nausea and vomiting." Current treatment options in gastroenterology vol. 11,2 (2008): 135-44. doi: https://doi.org/10.1007/s11938-008-0026-6
Chepyala P, Olden KW. Nausea and vomiting. Curr Treat Options Gastroenterol. 2008 Apr;11(2):135-44. doi: 10.1007/s11938-008-0026-6. PMID: 18321441.
Copy Download .nbib Format: NLM
Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting.

Journal of the advanced practitioner in oncology

Brafford MV, Glode A.
PMID: 25032030
J Adv Pract Oncol. 2014 Jan;5(1):24-9. doi: 10.6004/jadpro.2014.5.1.8.

Despite the appropriate use of pharmacologic and nonpharmacologic preventative measures, chemotherapy-induced nausea and vomiting (CINV) can be debilitating and can decrease quality of life for many patients. In addition, patients may be unwilling to continue chemotherapy treatment due to...

Cite
Brafford MV, Glode A. Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol. 2014;5(1):24-9doi: 10.6004/jadpro.2014.5.1.8.
Brafford, M. V., & Glode, A. (2014). Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. Journal of the advanced practitioner in oncology, 5(1), 24-9. https://doi.org/10.6004/jadpro.2014.5.1.8
Brafford, Megan V, and Glode, Ashley. "Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting." Journal of the advanced practitioner in oncology vol. 5,1 (2014): 24-9. doi: https://doi.org/10.6004/jadpro.2014.5.1.8
Brafford MV, Glode A. Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol. 2014 Jan;5(1):24-9. doi: 10.6004/jadpro.2014.5.1.8. PMID: 25032030; PMCID: PMC4093458.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 27 entries